文献速递生殖医学

近期使用枸橼酸氯米芬不影响单整倍体冻融胚胎移植周期的后续临床结局

Recent clomiphene citrate exposure does not impact subsequent clinical outcomes in single euploid frozen embryo transfer cycles.
PubMed 文献 · Hum Reprod · 2023-01-01

这项回顾性队列研究经倾向性评分匹配,比较了胚胎移植前90天内使用枸橼酸氯米芬(CC)的593例患者与1779例匹配对照,发现两组阳性妊娠试验率(75.7% vs 74.3%,P=0.79)及临床妊娠、持续妊娠、生化妊娠丢失、临床妊娠丢失率均无显著差异,调整后比值比为0.95(95%CI 0.76-1.18)。

要点

  • 近期CC暴露与单整倍体冻融胚胎移植后较低的着床潜力无关。
  • CC暴露组与对照组阳性妊娠试验率分别为75.7%和74.3%,无显著差异。
  • 多次连续CC周期也未显示与不良IVF结局相关。

核心结论

  • 近期CC暴露与单整倍体冻融胚胎移植后较低的着床潜力似乎无关。

研究设计与样本

  • 采用倾向性评分匹配的回顾性队列研究,纳入2016年9月至2022年9月在一家学术-私立ART中心接受自体单整倍体胚胎移植的所有患者。
  • 研究组为在冻融胚胎移植前至少90天使用过CC(用于诱导排卵和/或控制性卵巢刺激)的患者,对照组为在单整倍体胚胎移植前90天内未暴露于CC的倾向性评分匹配患者。

主要发现

  • 共比较593例移植前90天内使用CC的患者与1779例匹配对照。
  • 阳性妊娠试验率对照组为74.3%,CC暴露组为75.7%(P=0.79)。
  • 临床妊娠率对照组为64.0%,CC暴露组为65.0%(P=0.60);持续妊娠率对照组为51.8%,CC暴露组为53.2%(P=0.74)。
  • 生化妊娠丢失率对照组为15.7%,CC暴露组为14.03%(P=0.45);临床妊娠丢失率对照组为17.1%,CC暴露组为18.1%(P=0.71)。
  • 使用CC与较低着床率无关(调整后比值比0.95,95%CI 0.76-1.18);基于多个CC使用时段及连续累积CC周期数的亚分析也未观察到差异。

临床怎么用

  • 作者认为,因卵巢刺激或诱导排卵而在单整倍体冻融胚胎移植周期前使用CC的患者,可以放心,没有证据表明近期CC给药存在可能危及妊娠概率的残留效应。

局限性

  • 研究存在源于回顾性设计的内在偏倚。
  • 未测量CC血清水平,且亚分析样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do infertile couples who recently utilized clomiphene citrate (CC) for ovulation induction or ovarian stimulation (<90 days previously) followed by a single euploid embryo transfer (SEET) have lower implantation potential compared with patients who were not exposed to CC within 90 days before embryo transfer (ET)? SUMMARY ANSWER: There does not appear to be an association between recent CC exposure and lower implantation potential in patients who undergo a frozen embryo transfer (FET) of euploid embryos. WHAT IS KNOWN ALREADY: Clomiphene has been found to be associated with lower pregnancy rates when compared against other ovarian stimulation medications. The majority of published research about the effects of CC on implantation potential suggest an anti-estrogenic effect on the endometrium. Quality evidence and information about utilization of CC and its effect on implantation potential after euploid ETs is lacking in the literature. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study with propensity score matching was carried out. We included all patients that underwent an autologous SEET from September 2016 to September 2022 at a single academic-private ART center. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study group included patients that had utilized CC during either ovulation induction cycles and/or controlled ovarian stimulation at least 90 days before FET. A propensity score-matched control group of patients that were unexposed to CC within 90 days prior to SEET was used for comparisons. The primary outcome was positive pregnancy test (defined as a positive serum β-hCG measured 9 days after ET), with other outcomes including clinical pregnancy, ongoing pregnancy, biochemical pregnancy loss, and clinical pregnancy loss rates per SEET. Multivariate regression analyses fitted with generalized estimating equations were utilized to analyze if there was an association between CC utilization and IVF outcomes. Furthermore, the study evaluated the cumulative effect of CC and endometrial receptivity in vivo and subsequent IVF outcomes. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 593 patients with utilization of CC in <90 days before ET were compared with 1779 matched controls. Positive pregnancy test rates were comparable among the control group and the CC exposed groups, respectively (74.3% versus 75.7%, P = 0.79), as were clinical pregnancy (64.0% versus 65.0%, P = 0.60), ongoing pregnancy (51.8% versus 53.2%, P = 0.74), biochemical pregnancy loss (15.7% versus 14.03%, P = 0.45), and clinical pregnancy loss rates were also comparable among cohorts (17.1% versus 18.1%, P = 0.71). No association was found between utilization of clomiphene and lower implantation rates (adjusted odds ratio 0.95, 95% CI 0.76-1.18). Also, no differences were observed in sub-analyses based on multiple CC utilization periods. Finally, no association was found between the number of consecutive cumulative clomiphene cycles and sub-optimal IVF outcomes. LIMITATIONS, REASONS FOR CAUTION: The study has inherent bias that originated from its retrospective design. Serum levels of CC were not measured and sample size for the sub-analyses was small. WIDER IMPLICATIONS OF THE FINDINGS: There does not appear to be an association between recent CC exposure and lower implantation potential in patients who undergo a FET of euploid embryos. This finding remains consistent, even in patients who undergo multiple, consecutive clomiphene cycles prior to ET. There were no long-term effects of CC on endometrial development and clinical characteristics examined in this study. Patients that utilized CC medication prior to a SEET cycle for either ovarian stimulation or ovulation induction, can be assured that there is no evidence of a residual effect of recent CC administration that could jeopardize their pregnancy probability. STUDY FUNDING/COMPETING INTEREST(S): No funding was received for the realization of this study. A.C. is advisor and/or board member of Sema4 (stakeholder in data) and Progyny. The other authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Hernandez-Nieto C, Lee J, Alkon-Meadows T, et al. Recent clomiphene citrate exposure does not impact subsequent clinical outcomes in single euploid frozen embryo transfer cycles. Hum Reprod. 2023. PMID: 37075318. doi:10.1093/humrep/dead072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。